Assessment of the efficiency of treatment of dyslipidaemia in renal outpatients.
BACKGROUND
Lipid abnormalities, together with other co-existent risk factors, contribute to the accelerated atherosclerotic process, and consequently to the high incidence of cardiovascular disease, observed in end-stage renal patients. The objectives of this study were to determine the prevalence of dyslipidaemia and to assess how it is managed in a range of patients at four UK renal units.


METHODS
Patients with renal disease were recruited from the outpatient clinics of 4 UK hospitals. Individuals meeting the entry criteria were required to provide one sample of venous blood following a 12-hour fast. Lipid profiles were measured for each patient.


RESULTS
The study population consisted of 677 patients of which 276 (40.8%) were pre-dialysis patients with existing renal disease, 233 patients (34.4%) were receiving haemodialysis and 168 patients (24.8%) were receiving CAPD. Analysis showed that 64% of all patients had hypercholesterolaemia (defined according to Joint British Societies guidelines as LDL-cholesterol [LDL-C] >3.0 mmol/L [115 mg/dL] and/or total cholesterol [TC] >5.0 mmol/L [190 mg/dLl). Despite the high incidence of hypercholesterolaemia, only 16% of study participants were receiving lipid-lowering therapy. An LDL-C goal of <3.0 mmol/L (115 mg/dL) was achieved in 50.0% of patients receiving lipid-lowering treatment.


CONCLUSIONS
The widespread failure to treat hypercholesterolaemia in patients with renal dysfunction given their high risk of future cardiovascular events is a major cause for concern. The observation that many dialysis patients receiving lipid-lowering therapy had not achieved recommended LDL-C and TC levels suggests that more efficient treatment of dyslipidaemia may be indicated in this patient population.
Harris
Kevin
K
Department of Nephrology, Leicester General Hospital, UK. kevin.harris@uhl-tr.nhs.uk
Thomas
Mark
M
Short
Colin
C
Moore
Richard
R
D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000453:epidemiology* / Q000209:etiology / Q000628:therapy*; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications* / Q000453:epidemiology*; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D010043:Outcome and Process Assessment, Health Care / Q000706:statistics & numerical data*; D015995:Prevalence; D011787:Quality of Health Care / Q000706:statistics & numerical data*; D012307:Risk Factors; D006113:United Kingdom / Q000453:epidemiology
D008055:Lipids